Title:
Transcutaneous Electrical Nerve Stimulation (TENS): Current status of evidence

Target Journal: Pain Management

Authors:
Mark I. Johnson [1]
Gareth Jones [1]

Affiliations:
1. Centre for Pain Research, School of Clinical and Applied Sciences, Leeds Beckett University

Address for correspondence:
Professor Mark I Johnson
School of Clinical and Applied Sciences, Leeds Beckett University
City Campus, Leeds LS1 3HE, United Kingdom
Telephone: +44 (0)113 812 3083
e-mail: M.Johnson@leedbeckett.ac.uk

Article Type: Editorial

Keywords: Pain, Neuromodulation, Transcutaneous Electrical Nerve Stimulation

Conflict of interest: None.

Funding: None. There has been no funded writing assistance in the production of this manuscript
EDITORIAL

In the U.K. the National Institute of Health and Care Excellence (NICE) is in the processes of updating its guidance on the early management of non-specific low back pain and sciatica. The draft recommendations were released for public consultation on 24 March 2016 and concluded that all forms of exercise including stretching, strengthening, aerobic or yoga should be used in the first instance in conjunction with encouraging people to continue normal activities of daily living [1]. Physical and psychological therapies were also recommended for people who do not improve with previous treatments. The draft guidance states “Do not offer TENS [transcutaneous electrical nerve stimulation] for managing non-specific low back pain with or without sciatica.” based on a paucity of randomised controlled clinical trials (RCTs) on which to judge clinical efficacy. This not only raises doubt about the clinical efficacy of TENS for non-specific low back pain but also for the relief of pain for other conditions. Interestingly, in 2016 a systematic review of 13 studies (267 patients) evaluating TENS for chronic low back pain found that TENS provided a significant reduction in pain for 2 to 24 weeks [2]. The aim of this editorial is to analyse the current status of evidence for TENS for pain relief.

TENS is a technique that involves the delivery of mild pulsed electrical currents across the intact surface of the skin to stimulate low threshold nerves to relieve pain. A variety of health care practitioners (e.g. physicians, nurses, midwives and physiotherapists) offer TENS as a standalone treatment or combined with medication for symptomatic relief of inflammatory, neuropathic and musculoskeletal pain. TENS is popular with patients and practitioners because it is inexpensive, available without prescription, easy to self-administer and safe, with limited potential for toxicity or overdose [3]. One should be vigilant to claims by manufacturers that advanced technology incorporated into device design enables specific interactions with physiological mechanisms because any relationship between specific characteristics of electrical stimulation and physiological mechanisms may not influence clinically outcomes to any meaningful effect. Psychosocial factors have a strong influence on pain response. Thus, prescriptive, over-complicated TENS technique should be avoided. For most patients administering TENS to produce a strong non painful TENS sensation at the site of pain (conventional TENS) is effective.

Uncertainty about the usefulness of TENS has persisted since it was introduced into mainstream medicine in the early 1970s. Since then published research on the mechanisms of action, factors influencing response and clinical efficacy and effectiveness have risen exponentially. Randomised placebo-controlled clinical trials are used to assess clinical efficacy and for TENS will answer the question: Do you need to put batteries in the TENS device to get beneficial effects? A free text search in PubMed (01 July 2016) using the term ‘transcutaneous electrical nerve stimulation’ AND ‘pain’ found 682 hits for RCT, 195 hits for systematic review and 49 hits for meta-analysis. The majority of systematic reviews on TENS find inconclusive or conflicting evidence for clinical efficacy due to insufficient good quality research. However, subgroup
analyses suggest that TENS is superior to placebo when administered using strong non-painful stimulation within or close to site of pain (i.e. appropriate TENS technique) [4, 5].

The first systematic reviews on TENS were published in 1990s and challenged the belief that TENS was efficacious for acute pain [6, 7]. The first meta-analysis on TENS was conducted in 2003 and found that TENS reduced post-operative consumption of analgesic medication to a greater extent than placebo when TENS was administered using appropriate technique [5]. More recent systematic reviews confirm the efficacy of TENS for post-thoracotomy and post-sternotomy pain [8, 9]. The most recent Cochrane review on TENS on acute pain in adults included 19 RCTs (1346 participants) of procedural (cervical laser treatment, venepuncture, screening flexible sigmoidoscopy) and non-procedural pain (postpartum uterine contractions and rib fractures) [10]. A meta-analysis of six RCTs found that TENS reduced pain intensity by 31.79 mm to 17.46 mm (95% confidence intervals) on a 100 mm visual analogue scale compared with placebo. The likelihood of achieving ≥ 50% reduction in pain was 2.42 to 6.32 in favour of TENS over placebo (95% confidence intervals for relative risk, four RCTs). However, there was a high risk of bias due to inadequate sample sizes and unsuccessful blinding of treatment interventions so reviewers concluded that evidence was only tentative. Evidence to support the use of TENS for pain during childbirth is also tentative due to conflicting findings, although women receiving TENS are more ‘satisfied’ than those receiving placebo [11]. There is insufficient evidence for dysmenorrhoea, angina pectoris-like chest pain, and pain from lacerations, fractures, haematomas, contusions and dental procedures and that that exists is conflicting.

The largest meta-analysis on TENS was conducted a decade ago and provides evidence that TENS provides three times more relief of pain than placebo for chronic musculoskeletal conditions [12]. The analysis included 29 RCTs with 335 participants receiving placebo, 474 participants receiving TENS or percutaneous electrical nerve stimulation, and 418 participants crossed over to receive both active placebo electrical nerve stimulation. There were 32 comparisons on TENS. The review methodology was criticized for combining multiple diseases at the expense of homogeneity. To date, there are Cochrane and non-Cochrane systematic reviews on TENS for chronic pain, cancer pain, knee osteoarthritis, rheumatoid arthritis, neck pain, low back pain, chronic and recurrent headache, neuropathic pain, post-amputation pain, post-stroke pain, diabetic peripheral neuropathy, spinal cord injury, and central pain associated with multiple sclerosis. The majority of these reviews conclude that meaningful judgements on the clinical efficacy of TENS is not possible because RCTs were of insufficient quantity or had a high risk of bias associated with methodology. This concern is not unique to TENS as a review of 34 treatments (76 RCTs) for non-specific chronic low back pain found that study sample sizes were extremely low for most treatments [13].
There are more systematic reviews than RCTs evaluating TENS for some chronic pain conditions. For conditions where sufficient RCTs exist there is concern about trial fidelity with inadequate TENS technique and dosage common in RCTs [14]. The contradictory nature of evidence provided by TENS research has caused apparent inconsistencies in professional and regulatory body recommendations creating uncertainty for practitioners. For example, it is recommended in NICE guidelines that TENS should be offered for short-term relief of osteoarthritis [15], rheumatoid arthritis [16] and musculoskeletal pain secondary to multiple sclerosis [17], but not for non-specific low back pain [18]. Practitioners should be mindful that recommendations not to offer TENS are based on a paucity of evidence on which to make a judgement rather than evidence of inferiority or equivalence to placebo.

TENS should be considered a complex intervention influenced by a variety of factors, including the choice of TENS settings and pattern of TENS usage. The possible combinations of electrical output characteristics even on the simplest of TENS devices is vast, and the search for “optimal stimulator settings” has created a body of research literature that is impossible to interpret. This has fuelled myths about how best to use TENS in clinical practice. Research from studies using pain free participants exposed to experimentally induced pain suggest that favourable responses are obtained when the intensity of TENS is strong but not painful and administered at the site of pain (often termed “conventional TENS”). Thus, practitioners need to educate individuals about safe and appropriate TENS technique, including the need for patients to regularly self-administer TENS. Some patients stop using TENS because they find that the amount of effort needed to administer treatment is disproportionate to the amount of pain relief achieved. Recently, Gladwell et al. [19] conducted semi-structured interviews with 9 patients to explore their experiences of using TENS to manage chronic musculoskeletal pain. Challenges to optimize the use of TENS included frequently having to adjust electrode position and TENS settings to maintain pain relief. This research demonstrated the need to incorporate a learning phase to allow patients to optimize TENS usage. TENS success is optimised when new TENS users have realistic expectations from treatment and are provided with strategies to enable them to sustain motivation to self-administer treatment and troubleshoot declining response. A framework to support this approach is available in the book “Transcutaneous electrical nerve stimulation (TENS). Research to support clinical practice” [20].

Trying to interpret research on TENS is at best challenging and at worst futile because synthesising research findings is hindered by inconsistent terminology, variability in clinical technique, poor study design. Current research evidence suggests that it is reasonable to offer TENS as an adjunct to core treatment for most painful conditions, especially because it is inexpensive and has a favourable safety profile compared with long-term medication. Whether costs associated with TENS devices and accessories is covered by healthcare providers or patients is a matter for policymakers but practitioners need to be able to advise and educate patient about TENS because patients may purchase TENS without prescription. Investigators
may consider the use of an enriched enrolment, randomized withdrawal design using a two-stage recruitment process in future RCTs.

REFERENCES

